Our research findings revealed a significant upregulation in head and kidney CD4 and MHC-IIα in the APS–Vaccine group, indicating that the protective effect of VLPs might be due to their capability to stimulate both humoral and cellular immune responses. This evidence concerns the gene CD4 and autoimmune polyendocrinopathy.